Helicobacter pylori and interleukin 1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma

Journal of the National Cancer Institute

Volumn 94, Issue 22, 2002, Pages 1680-1687

  Figueiredo, Céu ^a   Machado, José Carlos ^b   Pharoah, Paul ^c   Seruca, Raquel ^b   Sousa, Sónia ^d   Carvalho, Ralph ^e   Capelinha, Ana Filipa ^e   Quint, Wim ^e   Caldas, Carlos ^c   van Doorn, Leen Jan ^e   Carneiro, Fátima ^e   Sobrinho Simões, Manuel ^e  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CAGA PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; UNCLASSIFIED DRUG; VACUOLATING TOXIN;

ADULT; AGED; ALLELE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CANCER RISK; CHRONIC GASTRITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK POPULATION; HOMOZYGOTE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL ANALYSIS; STOMACH CARCINOMA; TANDEM REPEAT;

EID: 0037146297     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.22.1680     Document Type: Article

References (36)

1. Blaser MJ. Ecology of Helicobacter pylori in the human stomach. J Clin Invest 1997;100:759-62.
2. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
3. Blaser MJ. Linking Helicobacter pylori to gastric cancer. Nat Med 2000;6:376-7.
4. Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
5. Mobley HL. Defining Helicobacter pylori as a pathogen: strain heterogeneity and virulence. Am J Med 1996;100:2S-9S.
6. Atherton JC. The clinical relevance of strain types of Helicobacter pylori. Gut 1997;40:701-3.
7. Atherton JC, Cao P, Peek RM, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995;270:17771-7.
8. van Doorn LJ, Figueiredo C, Sanna R, Pena AS, Midolo P, Ng EK, et al. Expanding allelic diversity of Helicobacter pylori vacA. J Clin Microbiol 1998;36:2597-603.
9. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer WA, et al. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori. Gastroenterology 1998;115:58-66.
10. Figueiredo C, van Doorn LJ, Nogueira C, Soares JM, Pinho C, Figueira P, et al. Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and reveal a high prevalence of infections with multiple strains. Scand J Gastroenterol 2001;36:128-35.
11. Nogueira C, Figueiredo C, Carneiro F, Taveira-Gomes A, Barreira R, Figueira P, et al. Helicobacter pylori genotypes may determine gastric histopathology. Am J Pathol 2001;158:647-54.
12. Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 1997; 112:92-9.
13. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996;93:14648-53.
14. Odenbreit S, Puls J, Sedlmaier B, Gerland E, Fischer W, Haas R. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000;287:1497-500.
15. Shimoyama T, Crabtree JE. Mucosal chemokines in Helicobacter pylori infection. J Physiol Pharmacol 1997;48:315-23.
16. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-5.
17. Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995;87:1777-80.
18. El Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
19. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, et al. Interleukin-1b and interleukin-1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001;121:823-9.
20. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interieukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:425-9.
21. Basso D, Scrigner M, Toma A, Navaglia F, Di Mario F, Rugge M, et al. Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res 1996;26:207-10.
22. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
23. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998;47:195-8.
24. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Chn Exp Immunol 1995;99:303-10.
25. El Omar EM. The importance of interleukin-1beta in Helicobacter pylori associated disease. Gut 2001;48:743-7.
26. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996;20:1161-81.
27. El Omar EM, Oien K, Murray LS, El Nujumi A, Wirz A, Gillen D, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of Helicobacter pylori. Gastroenterology 2000;118:22-30.
28. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
29. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, vander Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
30. van Doorn LJ, Figueiredo C, Rossau R, Jannes G, van Asbroeck M, Sousa JC, et al. Typing of the Helicobacter pylori vacA gene and detection of the cagA gene by PCR and reverse hybridization. J Clin Microbiol 1998;36:1271-6.
31. McColl KE, el-Omar E, Gillen D. Helicobacter pylori-induced alterations in gastric acid secretion. In: Moran AP, O'Morain CA, editors. Pathogenesis and host response in Helicobacter pylori infections. Bad Homburg (Germany): Normed Verlag; 1997. p. 119-27.
32. Gerhard M, Lehn N, Neumayer N, Boren T, Rad R, Schepp W, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigenbinding adhesin. Proc Natl Acad Sci U S A 1999;96:12778-83.
33. Azuma T, Ito S, Sato F, Yamazaki Y, Miyaji H, Ito Y, et al. The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma induced by Helicobacter pylori infection. Cancer 1998;82:1013-8.
34. Hunt RH, Fallone C, Veldhuyzen VZ, Sherman P, Smaill F, Thomson AB. Risks and benefits of Helicobacter pylori eradication: current status. Can J Gastroenterol 2002;16:57-62.
35. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999;159:142-8.
36. Parsonnet J, Harris RA, Hack HM, Owens DK. Modeling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-4.